VEGFA and renal cell carcinoma: However, VEGF TKI monotherapy would now be relevant for use only in a relatively small population of metastatic RCC patients, typically those with favorable risk disease per IMDC criteria, who would be appropriate for VEGF TKI monotherapy alone.